{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:23:09Z","timestamp":1788322989365,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-024-03376-9","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:02:09Z","timestamp":1724749329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib"],"prefix":"10.1186","volume":"26","author":[{"given":"Merete Lund","family":"Hetland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Soudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Jasper","family":"Deuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"3376_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12982-018-0080-z","volume":"15","author":"CM Schooling","year":"2018","unstructured":"Schooling CM, Jones HE. Clarifying questions about risk factors: predictors versus explanation. Emerg Themes Epidemiol. 2018;15:10.","journal-title":"Emerg Themes Epidemiol"},{"key":"3376_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.pmrj.2014.08.941","volume":"6","author":"KL Sainani","year":"2014","unstructured":"Sainani KL. Explanatory versus predictive modeling. PM R. 2014;6:841\u20134.","journal-title":"PM R"},{"key":"3376_CR3","doi-asserted-by":"publisher","first-page":"108497","DOI":"10.1016\/j.diabres.2020.108497","volume":"170","author":"TV Varga","year":"2020","unstructured":"Varga TV, Niss K, Estampador AC, Collin CB, Moseley PL. Association is not prediction: a landscape of confused reporting in diabetes - a systematic review. Diabetes Res Clin Pract. 2020;170:108497.","journal-title":"Diabetes Res Clin Pract"},{"key":"3376_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/XCE.0000000000000244","volume":"10","author":"Z Tian","year":"2021","unstructured":"Tian Z, McLaughlin J, Verma A, Chinoy H, Heald AH. The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Endocrinol Metab. 2021;10:125\u201331.","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"3376_CR5","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"key":"3376_CR6","first-page":"442","volume":"16","author":"A Berbudi","year":"2020","unstructured":"Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16:442\u20139.","journal-title":"Curr Diabetes Rev"},{"key":"3376_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","volume":"11","author":"MY Donath","year":"2011","unstructured":"Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98\u2013107.","journal-title":"Nat Rev Immunol"},{"key":"3376_CR8","doi-asserted-by":"publisher","first-page":"102506","DOI":"10.1016\/j.autrev.2020.102506","volume":"19","author":"M Mahler","year":"2020","unstructured":"Mahler M, Martinez-Prat L, Sparks JA, Deane KD. Precision medicine in the care of rheumatoid arthritis: focus on prediction and prevention of future clinically-apparent disease. Autoimmun Rev. 2020;19:102506.","journal-title":"Autoimmun Rev"},{"key":"3376_CR9","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287\u201393.","journal-title":"Arthritis Rheum"},{"key":"3376_CR10","doi-asserted-by":"publisher","first-page":"E84","DOI":"10.1016\/S2665-9913(19)30137-7","volume":"2","author":"A Pawar","year":"2020","unstructured":"Pawar A, Desai RJ, Gautam N, Kim SC. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020;2:E84\u201398.","journal-title":"Lancet Rheumatol"},{"key":"3376_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"3376_CR12","doi-asserted-by":"publisher","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","volume":"6","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6:e001395.","journal-title":"RMD Open"},{"key":"3376_CR13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard-2022-222405","volume":"81","author":"A Balanescu","year":"2022","unstructured":"Balanescu A, Citera G, Pascual-Ramos V, Bhatt DL, Connell CA, Gold D, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022;81:1491\u2013503.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1136\/annrheumdis-2015-207362","volume":"75","author":"JH Salmon","year":"2016","unstructured":"Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2016;75:1108\u201313.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR15","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914\u201320.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR16","doi-asserted-by":"publisher","first-page":"152050","DOI":"10.1016\/j.semarthrit.2022.152050","volume":"56","author":"C Yang","year":"2022","unstructured":"Yang C, Williams RD, Swerdel JN, Almeida JR, Brouwer ES, Burn E, et al. Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: a multinational real-world cohort analysis. Semin Arthritis Rheum. 2022;56:152050.","journal-title":"Semin Arthritis Rheum"},{"key":"3376_CR17","first-page":"3834","volume":"60","author":"S Krabbe","year":"2021","unstructured":"Krabbe S, Gr\u00f8n KL, Glintborg B, N\u00f8rgaard M, Mehnert F, Jarb\u00f8l DE, et al. Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model. Rheumatology (Oxford). 2021;60:3834\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"3376_CR18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1136\/annrheumdis-2013-203341","volume":"73","author":"A Zink","year":"2014","unstructured":"Zink A, Manger B, Kaufmann J, Eisterhues C, Krause A, Listing J, et al. Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis. 2014;73:1673\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR28","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895\u2013905.","journal-title":"Arthritis Rheum"},{"key":"3376_CR29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970\u201381.","journal-title":"Arthritis Rheum"},{"key":"3376_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617\u201329.","journal-title":"Arthritis Rheum"},{"key":"3376_CR31","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Y Tanaka","year":"2011","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3376_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","volume":"25","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25:514\u201321.","journal-title":"Mod Rheumatol"},{"key":"3376_CR33","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/annrheumdis-2015-208267","volume":"75","author":"PG Conaghan","year":"2016","unstructured":"Conaghan PG, \u00d8stergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75:1024\u201333.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR34","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","volume":"74","author":"DL Boyle","year":"2015","unstructured":"Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73:124\u201331.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75:687\u201395.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR37","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/art.40187","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69:1969\u201377.","journal-title":"Arthritis Rheumatol"},{"key":"3376_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet"},{"key":"3376_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u201370.","journal-title":"Arthritis Rheum"},{"key":"3376_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"3376_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li Z-G, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253\u201361.","journal-title":"Ann Intern Med"},{"key":"3376_CR42","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u201319.","journal-title":"N Engl J Med"},{"key":"3376_CR43","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u201386.","journal-title":"N Engl J Med"},{"key":"3376_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457\u201368.","journal-title":"Lancet"},{"key":"3376_CR45","doi-asserted-by":"publisher","first-page":"e001673","DOI":"10.1136\/rmdopen-2021-001673","volume":"7","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, et al. Efficacy and safety of tofacitinib modified-release 11\u00a0mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b\/4 methotrexate withdrawal non-inferiority study (ORAL Shift). RMD Open. 2021;7:e001673.","journal-title":"RMD Open"},{"key":"3376_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"3376_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.6339\/21-JDS1022","volume":"19","author":"SZ Sande","year":"2021","unstructured":"Sande SZ, Seng L, Li J, D\u2019Agostino R. Statistical learning in medical research with decision threshold and accuracy evaluation. J Data Sci. 2021;19:634\u201357.","journal-title":"J Data Sci"},{"key":"3376_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1109\/MIS.2020.2978066","volume":"36","author":"RT Nakatsu","year":"2021","unstructured":"Nakatsu RT. An evaluation of four resampling methods used in machine learning classification. IEEE Intell Syst. 2021;36:51\u20137.","journal-title":"IEEE Intell Syst"},{"key":"3376_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1613\/jair.953","volume":"16","author":"NV Chawla","year":"2002","unstructured":"Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: synthetic minority over-sampling technique. J Artif Intell Res. 2002;16:321\u201357.","journal-title":"J Artif Intell Res"},{"key":"3376_CR22","doi-asserted-by":"publisher","first-page":"e024372","DOI":"10.1136\/bmjopen-2018-024372","volume":"9","author":"U Hoang","year":"2019","unstructured":"Hoang U, Liyanage H, Coyle R, Godden C, Jones S, Blair M, et al. Determinants of inter-practice variation in childhood asthma and respiratory infections: cross-sectional study of a national sentinel network. BMJ Open. 2019;9:e024372.","journal-title":"BMJ Open"},{"key":"3376_CR23","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1093\/pubmed\/fdaa014","volume":"43","author":"S Smith","year":"2021","unstructured":"Smith S, Morbey R, de Lusignan S, Pebody RG, Smith GE, Elliot AJ. Investigating regional variation of respiratory infections in a general practice syndromic surveillance system. J Public Health (Oxf). 2021;43:e153\u201360.","journal-title":"J Public Health (Oxf)"},{"key":"3376_CR24","doi-asserted-by":"publisher","first-page":"1759720x2093605","DOI":"10.1177\/1759720X20936059","volume":"12","author":"F Sunzini","year":"2020","unstructured":"Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720x20936059.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3376_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2022","unstructured":"Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Sch\u00e4fer M, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022;81:41\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3376_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/BOR.0000000000000598","volume":"31","author":"M Jani","year":"2019","unstructured":"Jani M, Barton A, Hyrich K. Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? Curr Opin Rheumatol. 2019;31:285\u201392.","journal-title":"Curr Opin Rheumatol"},{"key":"3376_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.berh.2007.05.006","volume":"21","author":"DL Scott","year":"2007","unstructured":"Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:943\u201367.","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03376-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:09:20Z","timestamp":1724749760000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03376-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3376"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03376-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"This study was a post hoc analysis of existing data from the tofacitinib rheumatoid arthritis clinical development program. All included studies were approved by an Institutional Review Board or Independent Ethics Committee at each study site. Patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MLH has received grants from AbbVie, Biogen, Bristol Myers Squibb, Celltrion, Eli Lilly, Janssen Biologics B.V., Lundbeck Foundation, MSD, Pfizer Inc, Roche, Samsung Bioepis, Sandoz, and Novartis; honoraria from Medac, Pfizer Inc, and Sandoz; is a member of the advisory board for AbbVie; is a co-chair of EuroSpA; and has chaired for DANBIO DRQ.\u00a0AS is a principal investigator of RABBIT, which is jointly sponsored by a consortium of pharmaceutical manufacturers as follows: AbbVie, Amgen, Bristol Myers Squibb, Celltrion, Eli Lilly, Fresenius-Kabi, Galapagos, Hexal, MSD, Pfizer Inc, Samsung Bioepis, Sanofi-Aventis, UCB, and Viatris; and has received lecture fees from AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly, MSD, Pfizer Inc, Roche, Sanofi-Aventis, and UCB.\u00a0GB is a stockholder of Engineering Ingegneria Informatica, which acquired and merged with Fair Dynamics Consulting; and a paid consultant contracted by Health Services Consulting Corporation in connection with this study. Health Services Consulting Corporation was a paid contractor to Pfizer Inc in connection with the formal data analysis.\u00a0DS and JJD are employees and stockholders of Pfizer Inc.\u00a0RAE is the owner of Health Services Consulting Corporation and was a paid consultant to Pfizer Inc in connection with data generation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"List of baseline variables included in analysis (Table ); Percentage of available data across all baseline variables extracted from studies in the tofacitinib RA program (Fig. ); Feature importance of the Extreme Gradient Boosted prediction model for all studies (group 1) (Fig. S2). Feature importance of the Extreme Gradient Boosted prediction model for phase\u00a03 and 3b\/4 studies (group 2) (Fig. S3); Feature importance of the Extreme Gradient Boosted prediction model for ORAL Surveillance (NCT02092467; group 3) (Fig. S4).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Description of data"}}],"article-number":"153"}}